Introduction
Proliferative vitreoretinopathy (PVR) is the most common cause of failure in retinal detachment surgery. 1 PVR is characterized by formation of fibrovascular membranes within the vitreous cavity above and beneath the retina. These membranes cause subsequent tractional retinal detachment, resulting in serious vision problems. 2 Although the surgical and pharmacological treatment of PVR has improved, it is still difficult to treat. In cases where the treatment of PVR fails, the patient may become blind. The pathogenesis of PVR is not fully understood. It is known that during the development of PVR, numerous pathological cells (retinal pigmented cells, glial cells and fibroblasts) migrate on and beneath the retinal surface, vitreous cavity and subretinal space, and these cells play an important role in PVR progression.
There are various factors that contribute to the progression of PVR. 2 Among them, type ␤ transforming growth factor (TGF-␤) is believed to play a pivotal role in this process. The characteristic functions of TGF-␤, such as the stimulation of extracellular matrix production, contraction of cellular membrane, and induction of inflammation, are all negative factors in the progression of PVR. [3] [4] [5] [6] [7] Furthermore, TGF-␤ is abundant in the vitreous of PVR patients. 8 A large obstacle to investigating the role of TGF-␤ in vivo is the lack of any suitable methods to specifically inhibit TGF-␤ activity. TGF-␤1-and TGF-␤2-deficient mice have been developed by gene targeting. These mice have helped to elucidate the role of TGF-␤ in the early stages of life, but since these animals usually die by 3-4 weeks of age, they are useless for analyzing pathophysiology in adult mice. [9] [10] [11] A new method is needed to specifically block TGF-␤ signaling in the adult eye. We developed an adenovirus vector encoding a dominant negative TGF-␤ receptor, which can shut down the TGF-␤ signal transduction in transfected cells. 12 However, this approach blocks TGF-␤ signal transduction only in the infected cells. Since even the most effective gene transfer method cannot transfect every cell in the target tissue, this method is not ideal for studying the role of TGF-␤ in PVR. Recently, we constructed an adenoviral vector (AdT␤-ExR) expressing an ectodomain of the type II TGF-␤ receptor fused to the Fc portion of human IgG. 12, 13 The soluble receptor produced by the infected cells is secreted into the surrounding tissue and thus sequesters local TGF-␤ and inhibits its action in the entire surrounding tissue.
In this study, we demonstrate that adenovirusmediated transfection of a soluble TGF-␤ receptor is effective in reducing the expression of TGF-␤ in rabbit eyes. Furthermore, this approach reduces the severity of PVR in this animal model and thus demonstrates a possible method of gene therapy for the treatment of PVR.
Results

Inhibition of PVR
The PVR stage of each treated eye was graded by three observers (Table 1 ). In the two control groups (AdLacZ and BSS-injected eyes), the average stage of PVR steadily progressed over time. Typically, retinal detachment appeared after 3 days, and the fibrous membrane was formed on the retina after 7 days. By day 28, nearly all control eyes had stage 5 PVR, such that the total retina was detached and a thick membrane had formed ( Figures  1-3) . In eyes treated with AdT␤-ExR, the average stage of PVR did gradually increase over time, but the average was significantly lower than those of the control groups at all time-points from day 5 to day 28 (day 5; P = 0.00006676, day 7; P = 0.0000346, day 10; P = 0.00005288, day 14; P = 0.000171, day 28; P = 0.0013737). On day 28, 60% of AdT␤-ExR-treated eyes still had only stage 1 PVR features (Figures 1c and 3b) . All the eyes which had stage 2 or more on day 7 (49%) progressed PVR and had eventually stage 5 on day 28.
Quantification of TGF-␤ and soluble TGF-␤ receptor
In control eyes, the amount of TGF-␤1 was elevated on days 7 and 28 ( Table 2 ). The average amount of TGF-␤1 was smaller in AdT␤-ExR-treated eyes than in the controls at all time-points during treatment, but these differences were not statistically significant. The amount of TGF-␤2 was also elevated on days 7 and 28.
The soluble TGF-␤ receptor (T␤-ExR protein) was undetectable in control eyes throughout the experimental period. In AdT␤-ExR-treated animals, the T␤-ExR protein was absent before treatment, but present in large quantities on days 7 and 28 ( Table 2 ). It should be noted that the molar ratios of soluble receptor were much higher than the molar ratios of TGF-␤1 and TGF-␤2 on days 7 and 28. The molar ratios of T␤-ExR:TGF-␤1 were 24.7:1 and 31.5:1 at day 7 and day 28, respectively. The ratios of T␤-ExR:TGF-␤2 were 4.3:1 and 4.0:1 at day 7 and day 28, respectively.
Localization of TGF-␤ and soluble TGF-␤ receptor
In animals expressing AdT␤-ExR, the TGF-␤1 and TGF-␤2 proteins were localized mainly in the vitreous ( Figure  4a and b). The exogenously expressed TGF-␤ receptor, T␤-ExR, was present in the fibrovascular tissue on the retina and choroid (Figure 4c ). T␤-ExR was also observed on the surface of the medullary ray and in the vessels (Figure 4c ). Mild mononuclear cell infiltration was found on the retina. No T␤-ExR protein was found in the control animals ( Figure 4e ). X-gal staining of an AdLacZtreated eye showed that LacZ was mainly present in the 
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Figure 1 The stages of PVR in each group. The stage of PVR was evaluated at the indicated time-points for each rabbit injected with AdLacZ (a), BSS (b), and AdT␤-ExR (c).
fibroblasts in the retina (Figure 4f ). These results indicate that the adenovirus mainly infected the fibroblasts in the retina, while the secreted T␤-ExR protein spread out evenly in the vitreous.
Discussion
This study presents the first clear evidence showing that TGF-␤ does play a central role in the disease progression of PVR. Furthermore, gene transfer of TGF-␤ soluble receptor clearly inhibited the progression of experimental PVR in rabbits. This treatment inhibited not only the clinical retinal detachment, but also the formation of fibrovascular membrane associated with inflammatory cell infiltration. The tranfected soluble TGF-␤ receptor-Fc complex protein was produced in the eye, as confirmed by immunohistochemistry and ELISA. Furthermore, the amount of this protein was much higher than TGF-␤1 and TGF-␤2. In order to block TGF-␤ activity, the amount of soluble TGF-␤ receptor-Fc complex protein produced by gene transfer has to exceed that of TGF-␤1 and TGF-␤2 together in molar ratio, because soluble TGF-␤ receptors bind equally to TGF-␤1 and TGF-␤2. In this study, the TGF-␤ receptor-Fc complex protein exceeded the combined ligands (TGF-␤1 plus TGF-␤2) by a molar ratio of at 4.0:1 on day 7 and 3.7:1 on day 28. Thus, there was enough soluble TGF-␤ receptor to block TGF-␤ signaling, probably by absorbing TGF-␤ before it reached the native receptor. It is also possible that the soluble receptor works as a dominant-negative receptor, as has been shown in a case of the VEGF receptor. 14, 15 The observed effects of the transfection of the receptor did not seem to be caused by the immunoglobulin Fc portion of the soluble protein, because the injection of IgG itself, or an adenovirus encoding immunoglobulin, did not have any effect on PVR (data not shown).
In this study, the progression of PVR of the treated animals was inhibited significantly compared with that of control disease animals. Nonetheless, 20% of treated animals reached the maximum level of deterioration, namely stage 5, on day 28. The eyes which had stage 2 or more on day 7 eventually reached the advanced stages on day 28. This finding implied that TGF-␤ is important especially in the early phase of PVR. If the disease progression went beyond this early phase, the present method could not inhibit further progression. Another possibility is that there were many factors capable of inducing PVR other than TGF-␤. If those factors worked more strongly than TGF-␤ in the eye, the present method could not stop the disease progression. This is the clear limitation of this treatment and further study is still needed. The injection of an adenovirus vector into the vitreous cavity transfers the gene of interest mostly into the Muller cells. 16, 17 Using this method, an adenovirus vector encoding a dominant-negative TGF-␤ receptor could be administered, and it could block the signal transduction of TGF-␤ in transfected cells quite effectively. 18 However, the transfection efficiency of this method is limited; it is practically impossible to infect every cell whose TGF-␤ signal transduction would need to be blocked. In the present experiment, the injection of an adenovirus vector into the vitreous transferred the genes mostly to the fibroblasts that were injected to induce experimental PVR. The soluble receptor was produced by these nonretinal cells and secreted into the vitreous. Wherever this soluble protein reaches, it is able to produce an environment of intraocular tissue that is depleted of TGF-␤. Therefore, the adenovirus vector AdT␤-ExR did not need 
Figure 4 Localization of TGF-␤ and TGF-␤ receptor. In rabbits injected with AdT␤-ExR, antibodies against TGF-␤1 (a) and TGF-␤2 (b) showed that these proteins were localized in the vitreous. Staining with anti-human IgG reveals that the soluble TGF-␤ receptor was present in the fibrocellular tissue on the retina and choroid and on the surface of the medullary ray (c, d). No TGF-␤ receptor protein was found in the control animals (e). In the retina of an AdLacZ-treated eye, the staining of the transfected ␤-galactosidase was present only in the fibroblasts (f).
to infect every cell in order to block TGF-␤ action, in which case this soluble receptor approach has a great advantage. The present gene transfer method is also superior to protein transfer methods. The injection of a neutralizing antibody, for example, could also disrupt TGF-␤ signaling. However, a therapeutic protein can be degraded, and it may lose its biological activity soon after the injection. Thus, to maintain a therapeutic biological effect over a period of time, it would be necessary to inject a large amount of protein and/or give multiple injections of the protein. Gene transfer methods, on the other hand, can maintain the biological activity with a smaller amount of protein because it is produced continuously by the transfected cells over a long period of time. Indeed, in the present study, a single injection was sufficient to produce the protein of interest for 28 days. Since PVR is a chronic disease, gene transfer seems to be more suitable than the injection of protein as a therapeutic approach. [1] [2] [3] Although adenoviral gene transfer may accomplish gene expression for only a few weeks, it has a significant therapeutic effect in this experimental PVR model.
There are several concerns about the clinical use of adenoviral vectors for gene therapy. For example, the duration of gene expression from adenoviruses is comparatively short, usually less than 1 month. 19 However, this transient expression was enough to obtain a therapeutic effect to inhibit PVR in this system. It is possible that the soluble protein remained in the vitreous, maintaining the inhibitory effect on TGF-␤ for a long time. Furthermore, the inhibition of TGF-␤ during the initial phase of disease might work quite effectively to inhibit the subsequent deterioration of PVR in the present study. A previous study showed that the inhibition of TGF-␤ attenuated several important inflammatory responses in wound healing, including the degradation of extracellular matrix, production of proinflammatory cytokines, and chemoattraction of macrophages. 13 These proinflammatory reactions of TGF-␤ might have been strongly inhibited by the present treatment.
Another concern about using adenoviral vector systems is that they can induce a moderate inflammatory reaction. This inflammatory reaction is advantageous for gene therapy for cancer, but not for eye diseases. This inflammation is caused by an immune reaction against the adenovirus backbone protein, and the strength of inflammation is dependent on the amount (p.f.u.) of injected adenovirus. 19 In the present study, the amount of injected adenovirus was sufficient to inhibit PVR, but insufficient to induce significant inflammation. In our preliminary studies, we found a therapeutically beneficial range in the amount of virus (data not shown). Before clinical application, care must be taken to determine the optimal dose of therapeutic vector.
The present study shows that TGF-␤ is surely a pivotal protein in the progression of PVR and it may be an excellent target for the development of future PVR treatments. A combination of improved surgical methods, together with safe gene transfer technology, will bring about much better treatment for PVR.
Materials and methods
Replication-defective recombinant adenoviruses
The soluble TGF-␤ receptor used in this study consists of the entire extracellular domain of the human type II TGF-␤ receptor fused to the Fc portion of human IgG. The soluble TGF-␤ receptor expressed by adenovirus vector (AdT␤-ExR) was prepared by a previously described method. 12 Briefly, a replication-defective E1 Ϫ and E3 Ϫ adenoviral vector (AdT␤-ExR) expressing an entire extracellular domain of the type II human TGF-␤ receptor fused to the Fc portion of human IgG 1 , under the control of a CA promoter composing a cytomegalovirus enhancer and a chicken ␤-actin promoter, was prepared by in vitro homologous recombination in 293 cells. 20, 21 An adenovirus expressing bacterial ␤-galactosidase (AdLacZ) was also prepared. 22 The titer of each virus stock was assessed by a plaque formation assay in 293 cells, and titers were calculated as plaque-forming units (p.f.u.). All manipulations of adenoviruses were done in accordance with both institutional and national biosafety restrictions.
Fibroblast culture
Rabbit conjunctival fibroblasts were collected from adult pigmented rabbit eyes as previously described, 23 with minor modifications. All animals were killed with an overdose of intravenously injected pentobarbital, and a conjunctival resection was performed. Primary cultures of conjunctival fibroblasts were established in 12-well culture plates (Corning Glass Works, Corning, NY, USA) and incubated with Dulbecco's modified Eagle medium (Gibco, Grand Island, NY, USA) containing 10% fetal bovine serum (Gibco) and penicillin-streptomycin (Gibco). All fibroblasts used were between passage 3 and 5. All the methods for securing animal tissues were humane, approved by the Kyushu University Graduate School of Medicine, and in strict compliance with the Association for Research in Vision and Ophthalmology Resolution on the Use of Animals in Research.
Induction of PVR and injection of adenovirus
Experimental PVR was induced by a method previously described, with minor modifications. 23, 24 Briefly, adult pigmented rabbits (2.0-2.5 kg) were anesthetized with an intramuscular injection of ketamine hydrochloride (14 mg/kg) and xylazine hydrochloride (14 mg/kg). The pupils were dilated with one drop of 10% phenylephrine hydrochloride, 1% tropicamide, and 1% atropine sulfate. One eye of each rabbit was injected with 5.0 × 10 5 cells in 0.1 ml BSS solution in the vitreous cavity through the pars plana, following pars plana vitrectomy. Immediately thereafter, the eyes received either a single intravitreal injection of AdT␤-ExR (0.1 ml of 10 3 p.f.u.) (n = 5) or AdLacZ (0.1 ml of 10 3 p.f.u.) (n = 5). A similar number of eyes received only fibroblasts and balanced salt solution (BSS) and these provided a second control (n = 5). All injected eyes were ophthalmoscopically examined by three masked observers on days 1, 3, 5, 7, 10, 14 and 28 after surgery. PVR was classified into six stages using the clinical criteria described by Fastenberg et al (Table 1) . 25 
ELISA for TGF-␤ and soluble TGF-␤ receptor
Enzyme-linked immunosorbent assays (ELISA) were used to measure the amount of soluble TGF-␤ receptor, TGF-␤1, and TGF-␤2 proteins in the vitreous. Samples of vitreous were taken on day 0 (before injection), day 7, and day 28, as described previously.
12,24 TGF-␤1 and TGF-␤2 protein in the vitreous were assayed using a kit (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions. 24 To measure the amounts of the receptor, we set up an ELISA assay that detected the IgG domain of the recombinant receptor. A 96-well microplate was coated with 500 ng of a rabbit anti-human IgG (CH2 fragment-specific; Dako) in sodium carbonate buffer (pH 9.5) overnight at 4°C. After washing the plate three times with Tris-buffered saline containing 0.05% Tween 20 (TBST), TBST solution containing 2.5% blockade (Snow Brand, Tokyo, Japan) was added to block nonspecific binding. The plate was incubated for 1 h at room temperature, then washed three times with TBST. A sample of vitreous was added to each well of the plate. To make the standard curve, we used 100 l of the appropriate dilutions of human IgG (Dako). The reactions were incubated for 1 h at room temperature. After washing with TBST, a polyclonal horseradish peroxidase-conjugated rabbit anti-human IgG (∂-chain specific; Dako) was added, and the plate was incubated for 1 h at room temperature. Substrate solution containing 3,3'5,5'-tetramethylbenzidine (TMBZ; Sumitomo Bakelite, Tokyo, Japan) was added to each well and incubated for 15 min at room temperature. The absorbance at 492 nm was measured with a microplate reader.
Localization of TGF-␤ and soluble TGF-␤ receptor
Additional rabbits were treated with AdT␤-ExR (n = 4) or AdLacZ (n = 4), as described above. The rabbits that received AdT␤-ExR were enucleated on day 14, and the eyes were fixed, paraffin-embedded, sectioned and stained by routine hematoxylin and eosin staining. The distribution of the soluble TGF-␤ receptor (T␤-ExR protein), TGF-␤1, and TGF-␤2 were examined by immunohistochemistry. 14 The soluble TGF-␤ receptor was stained with a goat anti-human immunoglobulin Fc polyclonal antibody (Dakopatts, Glostrup, Denmark). This antibody did not crossreact with rabbit immunoglobulins (data not shown). In order to detect transfected cells, the eyes that received AdLacZ were enucleated on day 5 and stained with X-gal (Gibco) as previously described. 16 
Statistical analysis
The stages of PVR in the control groups (AdLacZ group or BSS-injected group) were compared with those in the treated group (AdT␤-ExR group) using the Mann-Whitney U-test. A P value of 0.05 or less was considered statistically significant.
